12:00 AM
 | 
Oct 26, 1998
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AnergiX AG284 myelin basic protein complexed to HLA-DR2 major histocompatibility complex molecule: Phase I

ANRG said that a placebo-controlled Phase I dose-escalation study in 33 patients showed safety and tolerability of its autoimmune treatment to suppress T cells specifically involved...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >